Bedfont® Scientific Limited Appoints Michael Bencak to Board of Directors to Accelerate International Market Expansion

Bedfont® Scientific strengthens its board with Michael Bencak, aiming to expand its global reach in non-invasive breath analysis and respiratory technology.

By: AXL Media

Published: Mar 17, 2026, 9:09 AM EDT

Source: Information for this report was sourced from Bedfont® Scientific Ltd

Strategic Leadership Expansion in the Medical Technology Sector

Bedfont® Scientific Ltd, a prominent manufacturer in the breath analysis industry for nearly five decades, has officially expanded its Board of Directors to navigate a period of rapid institutional growth. The company announced the appointment of Michael Bencak, an executive with over two decades of experience leading healthcare and life science organizations through complex international expansions. This strategic hire is designed to leverage Bencak’s history of scaling businesses to unlock new potential within Bedfont’s existing portfolio of respiratory diagnostic tools.

Building on Recent Institutional Investment and Growth

The leadership change comes as a direct follow up to the 2025 acquisition of a majority stake in the company by Keensight, a private equity firm. According to company statements, the integration of new board level expertise is essential for managing the capital and operational requirements of a global med-tech firm in its current phase. By adding Bencak’s strategic approach to the existing executive structure, Bedfont® aims to solidify its status as a world leader in non-invasive medical devices that assist healthcare professionals in immediate clinical investigations.

Enhancing Global Partnerships and Distribution Networks

Operating through a network of over 100 distributors worldwide, Bedfont® relies heavily on technical innovation and professional business practices to maintain its market share. CEO Jason Smith noted that Bencak’s track record in building global partnerships will be invaluable as the company continues its mission to advance breath analysis technology. The appointment is expected to streamline the company’s supply chain and partnership models, ensuring that cutting edge diagnostic products reach international markets with greater efficiency and regulatory compliance.